Anbio Biotechnology (NNNN) - יחס מהיר

The GURU.Markets terminal provides a chart of the quick ratio for Anbio Biotechnology (NNNN), where the 355.17 level serves as a critical benchmark. Moderate volatility confirms the average predictability of cash flows from equipment sales. Growth is driven by the expansion of budget analyzers into emerging markets, while operational flexibility is achieved by outsourcing reagent production to third-party contractors.

Anbio Biotechnology stability relies on the diversification of its medical product lines, which mitigates certification and distribution risks in Asia. The quick liquidity vector, recorded at 355.17, reflects the company's ability to settle short-term liabilities without liquidating inventory, utilizing only cash and accounts receivable, which serves as a critical filter when determining the asset's fair value.